ExpreS2ion Biotechnologies is a world leading contract research organization (CRO) for the production in Drosophila Schneider-2 (S2) cells using its proprietary and complete S2 recombinant protein technology ExpreS2.
ExpreS2ion Biotechnologies – production in Drosophila S2 cells
Biopharmaceutical proteins can be produced at competitive cost with the Drosophila S2 expression system and ExpreS2ion Biotechnologies offers unrivalled expertise with this technology using its system of vectors, optimized medium and S2 cells. Thanks to ExpreS2ion tools, up to ten fold increases in protein production can be achieved compared to currently available methods for S2 expression. ExpreS2 expression system is able to produce pharmaceutical proteins with authentic protein structure, mammalian-like glycosylation and high protein yields, in a timely and cost-effective manner. ExpreS2ion’s package offers ease of use, consistent high yields, reproducibility, up-scalability and compliance with cGMP and regulatory requirements. Moreover, ExpreS2ion also offers an expert service package including cell line development, cell banking, etc… Additionally, both N-ter and C-terminally HIS-tagged ligation independent cloning (LIC) enabled vectors are available for both intra- and extracellular expression. Furthermore, ExpreS2 Insect-TR is a specially designed liposome formulation offering high transfection efficiencies for S2 cells in serum-free medium.
ExpreS2ion is a biotech company based in Denmark. Management Team is composed by Charlotte Dyring (CEO), Wian de Jongh (CSO) and Sancha Salgueiro. Board of Directors is composed by Martin Roland Jensen, Allan Rosetzsky and Jesper Roested. And Scientific Advisory Board is composed by Jens Gram and Michael Sundström. Several proteins produced by the S2 system have already been approved by the US FDA and European regulatory bodies for human clinical trials.
More about ExpreS2ion Biotechnologies : www.expres2ionbio.com